Business Wire

Probitas Partners Global Growth Continues With the Announcement of New Managing Directors

Jaa

Probitas Partners is excited to announce the promotion of four new managing directors who will continue to drive the firm’s growth. These promotions are in recognition of contributions to the success of the firm and in anticipation of continued success on behalf of our fund sponsor and institutional investor clients.

Additionally, Probitas is excited to expand its real estate advisory capabilities to include providing bespoke access to large scale U.S. commercial real estate opportunities to a targeted universe of the most active and sophisticated investors globally.

Probitas Partners was founded in 2001 and is a leading independent global placement advisory firm. The firm continues to be led by the longest-standing senior management team of any global placement advisor. The founders of Probitas congratulate their colleagues on their promotions and look forward to the next decade of great partnerships.

Caryn Feinberg has been promoted to Managing Director on the project management team. She is primarily responsible for leading origination efforts in the U.S. Prior to joining Probitas Partners, Caryn worked for SecondMarket, Inc. and before that, was Director of Investor Relations for Global Infrastructure Partners, a private equity infrastructure fund. Caryn previously also worked for Citigroup in New York.

Haakon Gresvig has been promoted to Managing Director on the relationship management (Distribution) team. He is primarily responsible for maintaining key investor relationships in Europe and the Middle East as well as acting as head of Probitas’ European office. Prior to joining Probitas Partners, Haakon was a Director at Wedge Alternatives, a boutique placement agent in London focused on raising capital for private equity and hedge funds. Prior to that, Haakon worked at Goldman Sachs in New York and London.

Ray Tsao has been promoted to Managing Director on the project management team. He is primarily responsible for leading fund due diligence and execution of alternative asset fund placement processes. Ray started with Probitas in 2009 and has been associated with and led many of our successful fundraises. Prior to joining Probitas Partners, Ray served as an investment banking associate in the Technology Group at Credit Suisse in San Francisco.

John Caley joins Probitas Partners as a Managing Director – Direct Real Estate. John brings 27 years of industry experience in identifying large-scale assets with unique investment attributes (off-market, broker-controlled pocket listings, direct ownership, sensitive timing, etc.) that create bespoke and often time-sensitive direct investment opportunities. Prior to joining Probitas Partners, John was a Senior Managing Director at Grubb & Ellis’ Investment Management Platform and has held senior executive positions with Gemini Rosemont, Rexford Industrial, Transwestern and PM Realty Group.

“We are pleased to acknowledge the growing strength and capabilities of our team. This has resulted in our promotion of these individuals. It is very gratifying for the three founding partners of Probitas Partners to be able to attract and retain such a high-quality team that will continue to build on our 17-year track record of success,” said Craig Marmer, a founding partner.

In addition, “Recognizing the clear market trend for large institutional investors to seek direct commercial real estate exposure, we are excited to expand our global real estate advisory business to include discrete access to very large-scale commercial real estate investment opportunities across the U.S.,” said Michael Hoffmann, a founding partner.

About Probitas Partners

Rewarding Partnerships Since 2001

For 17 years Probitas Partners has identified and affiliated with the highest quality established and emerging alternative investment fund managers from around the world, advising on over 90 fundraises and franchise developments and representing over $68 billion of capital commitments for private equity, real estate, infrastructure, real assets and credit funds. As part of the firm’s commitment to excellence and in support of our clients’ investment goals, we continue to deliver the market’s leading independent research offering, providing institutional investors with gratis access to our propriety data, surveys, white papers and tailored landscapes by geography, sector and strategy.

Contact information

Probitas Partners
Michael Hoffmann, 415-402-0700
Co-Founder & Managing Director

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 13:45Tiedote

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 12:10Tiedote

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting21.10.2018 01:30Tiedote

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 20:37Tiedote

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10Tiedote

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme